Bavarian NordicDK0015998017BAVABAVA
Financials
Market Cap
$1.64B5Y beta
1.67EPS (TTM)
$2.779Free Float
77.98MP/E ratio (TTM)
7.57Revenue (TTM)
$1.01BEBITDA (TTM)
$382.38MFree Cashflow (TTM)
$20.25MPricing
Analyst Ratings
The price target is $38.34 and the stock is covered by 7 analysts.
Buy
6
Hold
1
Sell
0
Information
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.